Search results
Jump to navigation
Jump to search
- :Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD ...ile.v0.1_2016.04.15b.docx | QIBA DRAFT Profile with tracked changes - {Dr. Mozley}]] ''April 15, 2016''5 KB (673 words) - 18:46, 21 December 2023
- ...docx | QIBA DRAFT Profile with tracked changes for recent additions - {Dr. Mozley}]] ''March 21, 2016'' ...docx | QIBA DRAFT Profile with tracked changes for recent additions - {Dr. Mozley}]] ''March 16, 2016''2 KB (221 words) - 20:27, 17 March 2017
- ...Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]606 bytes (81 words) - 14:35, 9 April 2015
- *Mozley PD (pharma industry co-chair) Merck & Co Inc/PhRMA36 KB (5,187 words) - 16:42, 23 July 2009
- ...Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]235 bytes (28 words) - 18:45, 27 October 2008
- • Mozley PD, (pharma industry co-chair) Merck & Co Inc/PhRMA40 KB (5,805 words) - 18:35, 4 September 2009
- *Mozley PD (pharma industry co-chair) Merck & Co Inc/PhRMA36 KB (5,191 words) - 14:47, 22 June 2009
- *Mozley PD (pharma industry co-chair) Merck & Co Inc/PhRMA31 KB (4,311 words) - 20:35, 29 May 2009
- *Mozley PD (pharma industry co-chair) Merck & Co Inc/PhRMA31 KB (4,311 words) - 20:44, 29 May 2009
- *Mozley PD (pharma industry co-chair) Merck & Co Inc/PhRMA35 KB (4,981 words) - 14:36, 8 June 2009